Peptide vaccines in breast cancer: The immunological basis for clinical response

Biotechnology Advances

Volumn 33, Issue 8, 2015, Pages 1868-1877

  de Paula Peres, Lívia ^a   da Luz, Felipe Andrés Cordero ^a   dos Anjos Pultz, Brunna ^a   Brígido, Paula Cristina ^a   de Araújo, Rogério Agenor ^a   Goulart, Luiz Ricardo ^a   Silva, Marcelo José Barbosa ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Breast cancer; Breast cancer immunotherapy; Breast cancer therapy; Peptide based vaccines; Tumor associated antigens

Indexed keywords

ANTIGENS; EPITOPES; PEPTIDES; PROTEINS; T-CELLS; TUMORS; VACCINES;

BREAST CANCER; CLINICAL OUTCOME; CLINICAL RESPONSE; HUMAN LEUKOCYTE ANTIGEN; MULTIPLE TARGETS; NATURAL VARIATION; PEPTIDE VACCINES; PROSTATE CANCERS;

DISEASES;

ANIMALIA;

ANTIGEN; CANCER; DISEASE TREATMENT; GENE EXPRESSION; IMMUNE RESPONSE; PEPTIDE; PROTEIN; TUMOR; VACCINE;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; ERBB2 PROTEIN, HUMAN; HLA A2 ANTIGEN; PEPTIDE; SUBUNIT VACCINE; TUMOR ANTIGEN;

ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); FEMALE; HUMAN; IMMUNOLOGY;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; EPITOPES; FEMALE; HLA-A2 ANTIGEN; HUMANS; PEPTIDES; RECEPTOR, ERBB-2; VACCINES, SUBUNIT;

EID: 84961885009     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2015.10.013     Document Type: Review

References (85)

1. Abdel-Aal A.B., Lakshminarayanan V., Thompson P., Supekar N., Bradley J.M., Wolfert M.A., et al. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. Chembiochem 2014, 15:1508-1513.
2. Anderson K.S. Tumor vaccines for breast cancer. Cancer Investig. 2009, 27:361-368.
3. Babu G., Almel S.V., Aggarwal S., Jalali R. A Randomized, Double-Blind, Controlled Phase III Study of Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Combination with Hormonal Treatment Versus Hormonal Treatment Alone for First-Line Therapy of Post-Menopausal Women with Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer 2011.
4. Bailur J.K., Gueckel B., Derhovanessian E., Pawelec G. Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Breast Cancer Res. 2015, 17:34.
5. Berinstein N.L., Karkada M., Morse M.A., Nemunaitis J.J., Chatta G., Kaufman H., et al. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J. Transl. Med. 2012, 10:156.
6. Blum J.S., Wearsch P.A., Cresswell P. Pathways of antigen processing. Annu. Rev. Immunol. 2013, 31:443-473.
7. Bolhassani A., Safaiyan S., Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol. Cancer 2011, 10:3.
8. Bourgeois C., Tanchot C. Mini-review CD4 T cells are required for CD8 T cell memory generation. Eur. J. Immunol. 2003, 33:3225-3231.
9. Cai H., Sun Z.Y., Chen M.S., Zhao Y.F., Kunz H., Li Y.M. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells. Angew. Chem. Int. Ed. Engl. 2014, 53:1699-1703.
10. Carmichael M.G., Benavides L.C., Holmes J.P., Gates J.D., Mittendorf E.A., Ponniah S., et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States military cancer institute clinical trials group study I-04. Cancer 2010, 116:292-301.
11. Chamuleau M.E., Souwer Y., Van Ham S.M., Zevenbergen A., Westers T.M., Berkhof J., et al. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res. 2004, 64:5546-5550.
12. Chung M.A., Luo Y., O'Donnell M., Rodriguez C., Heber W., Sharma S., et al. Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine. Cancer Res. 2003, 63:1280-1287.
13. Cloosen S., Arnold J., Thio M., Bos G.M., Kyewski B., Germeraad W.T. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res. 2007, 67:3919-3926.
14. Criscitiello C. Tumor-associated antigens in breast cancer. Breast Care (Basel) 2012, 7:262-266.
15. Cui W., Kaech S.M. Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol. Rev. 2010, 236:151-166.
16. Degregorio M., Degregorio M., Wurz G.T., Wurz G.T., Gutierrez A., Gutierrez A., et al. L-BLP25 vaccine plus letrozole for breast cancer: is translation possible?. Oncoimmunology 2012, 1:1422-1424.
17. Disis M.L., Salazar L.G., Knutson K.L. Peptide-based vaccines in breast cancer. Breast Dis. 2004, 20:3-11.
18. Ellsworth R.E., Decewicz D.J., Shriver C.D., Ellsworth D.L. Breast cancer in the personal genomics era. Curr. Genomics 2010, 11:146-161.
19. Even-Desrumeaux K., Baty D., Chames P. State of the art in tumor antigen and biomarker discovery. Cancers (Basel) 2011, 3:2554-2596.
20. Finn O.J. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 2003, 3:630-641.
21. Gates J.D., Clifton G.T., Benavides L.C., Sears A.K., Carmichael M.G., Hueman M.T., et al. Circulating regulatory T cells (CD4 + CD25 + FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine 2010, 28:7476-7482.
22. Gilewski T., Adluri S., Ragupathi G., Zhang S., Yao T.J., Panageas K., et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 2000, 6:1693-1701.
23. Gingras I., Azim H.A., Ignatiadis M., Sotiriou C. Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies. Clin. Adv. Hematol. Oncol. 2015, 13:372-382.
24. Gulley J.L., Arlen P.M., Tsang K.Y., Yokokawa J., Palena C., Poole D.J., et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 2008, 14:3060-3069.
25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
26. Holmes J.P., Benavides L.C., Gates J.D., Carmichael M.G., Hueman M.T., Mittendorf E.A., et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J. Clin. Oncol. 2008, 26:3426-3433.
27. Holmes J.P., Clifton G.T., Patil R., Benavides L.C., Gates J.D., Stojadinovic A., et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2011, 117:463-471.
28. Imanishi T., Kamigaki T., Nakamura T., Hayashi S., Yasuda T., Kawasaki K., et al. Correlation between expression of major histocompatibility complex class I and that of antigen presenting machineries in carcinoma cell lines of the pancreas, biliary tract and colon. Kobe J. Med. Sci. 2006, 52:85-95.
29. Jager E., Ringhoffer M., Altmannsberger M., Arand M., Karbach J., Jager D., et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 1997, 71:142-147.
30. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
31. Kaiser A., Gaidzik N., Westerlind U., Kowalczyk D., Hobel A., Schmitt E., et al. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response. Angew. Chem. Int. Ed. Engl. 2009, 48:7551-7555.
32. Karkada M., Weir G.M., Quinton T., Fuentes-Ortega A., Mansour M. A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery. Vaccine 2010, 28:6176-6182.
33. Karkada M., Weir G.M., Quinton T., Sammatur L., MacDonald L.D., Grant A., et al. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses. J. Immunother. 2010, 33:250-261.
34. Karkada M., Berinstein N.L., Mansour M. Therapeutic vaccines and cancer: focus on DPX-0907. Biologics 2014, 8:27-38.
35. Karkada M., Quinton T., Blackman R., Mansour M. Tumor inhibition by DepoVax-based cancer vaccine is accompanied by reduced regulatory/suppressor cell proliferation and tumor infiltration. ISRN Oncol. 2013, 2013:753427.
36. Karyampudi L. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin. Cancer Res. 2010, 16:825-834.
37. Keogh E., Fikes J., Southwood S., Celis E., Chesnut R., Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J. Immunol. 2001, 167:787-796.
38. Kohlgraf K.G. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol. Immunother. 2004, 53:1068-1084.
39. Khazaie K., Bonertz A., Beckhove P. Current developments with peptide-based human tumor vaccines. Curr. Opin. Oncol. 2009, 21:524-530.
40. Kobayashi H., Nagato T., Oikawa K., Sato K., Kimura S., Aoki N., et al. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin. Cancer Res. 2005, 11:3869-3878.
41. Kruger C., Greten T.F., Korangy F. Immune based therapies in cancer. Histol. Histopathol. 2007, 22:687-696.
42. Lage A. Immunotherapy and complexity: overcoming barriers to control of advanced cancer. MEDICC Rev. 2014, 16:65-72.
43. Lakshminarayanan V., Thompson P., Wolfert M.A., Buskas T., Bradley J.M., Pathangey L.B., et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:261-266.
44. Lu J., Higashimoto Y., Appella E., Celis E. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J. Immunol. 2004, 172:4575-4582.
45. Mangalam A.K., Taneja V., David C.S. HLA class II molecules influence susceptibility versus protection in inflammatory diseases by determining the cytokine profile. J. Immunol. 2013, 190:513-518.
46. Marshall J.L., Gulley J.L., Arlen P.M., Beetham P.K., Tsang K.Y., Slack R., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 2005, 23:720-731.
47. Mehta N.R., Wurz G.T., Burich R.A., Greenberg B.E., Griffey S., Gutierrez A., et al. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice. Clin. Cancer Res. 2012, 18:2861-2871.
48. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
49. Mittendorf E.A., Clifton G.T., Holmes J.P., Clive K.S., Patil R., Benavides L.C., et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012, 118:2594-2602.
50. Mittendorf E.A., Clifton G.T., Holmes J.P., Schneble E., van Echo D., Ponniah S., et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann. Oncol. 2014, 25:1735-1742.
51. Mohit E., Hashemi A., Allahyari M. Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert. Rev. Clin. Immunol. 2014, 10:927-961.
52. Morita R., Hirohashi Y., Sato N. Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity. Immunotherapy 2012, 4:1103-1105.
53. Morse M.A., Secord A.A., Blackwell K., Hobeika A.C., Sinnathamby G., Osada T., et al. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin. Cancer Res. 2011, 17:3408-3419.
54. Myc L.A., Gamian A., Myc A. Cancer vaccines. Any future?. Arch. Immunol. Ther. Exp. 2011, 59:249-259.
55. Ossendorp F., Mengede E., Camps M., Filius R., Melief C.J. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 1998, 187:693-702.
56. Pardoll D.M., Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 1998, 10:588-594.
57. Patil R., Clifton G.T., Holmes J.P., Amin A., Carmichael M.G., Gates J.D., et al. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J. Am. Coll. Surg. 2010, 210:140-147.
58. Peoples G.E., Gurney J.M., Hueman M.T., Woll M.M., Ryan G.B., Storrer C.E., et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol. 2005, 23:7536-7545.
59. Perret R., Sierro S.R., Botelho N.K., Corgnac S., Donda A., Romero P. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res. 2013, 73:6597-6608.
60. Pilla L., Rivoltini L., Patuzzo R., Marrari A., Valdagni R., Parmiani G. Multipeptide vaccination in cancer patients. Expert. Opin. Biol. Ther. 2009, 9:1043-1055.
61. Purcell A.W., McCluskey J., Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 2007, 6:404-414.
62. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19:1423-1437.
63. Ramakrishna V., Ross M.M., Petersson M., Gatlin C.C., Lyons C.E., Miller C.L., et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int. Immunol. 2003, 15:751-763.
64. Rapetti L., Meunier S., Pontoux C., Tanchot C. CD4 help regulates expression of crucial genes involved in CD8 T cell memory and sensitivity to regulatory elements. J. Immunol. 2008, 181:299-308.
65. Reichenbach D.K., Finn O.J. Early in vivo signaling profiles in MUC1-specific CD4 T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology 2013, 2.
66. Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J., Yannelli J.R., Rosenberg S.A. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 1996, 88:100-108.
67. Schimanski C.C., Mohler M., Schon M., van Cutsem E., Greil R., Bechstein W.O., et al. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. BMC Cancer 2012, 12:144.
68. Schlom J., Hodge J.W. The diversity of T-cell co-stimulation in the induction of antitumor immunity. Immunol. Rev. 1999, 170:73-84.
69. Sears A.K., Perez S.A., Clifton G.T., Benavides L.C., Gates J.D., Clive K.S., et al. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert. Opin. Biol. Ther. 2011, 11:1543-1550.
70. Seliger B., Ritz U., Abele R., Bock M., Tampe R., Sutter G., et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 2001, 61:8647-8650.
71. Senkus E., Kyriakides S., Penault-Llorca F., Poortmans P., Thompson A., Zackrisson S., et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013, 24(Suppl. 6):vi7-v23.
72. Shastri N., Schwab S., Serwold T. Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. Annu. Rev. Immunol. 2002, 20:463-493.
73. Singh P.K., Hollingsworth M.A. Cell surface-associated mucins in signal transduction. Trends Cell Biol. 2006, 16:467-476.
74. Smyth M.J., Hayakawa Y., Takeda K., Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2002, 2:850-861.
75. Soares M.M., Mehta V., Finn O.J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 2001, 166:6555-6563.
76. Surman D.R., Dudley M.E., Overwijk W.W., Restifo N.P. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J. Immunol. 2000, 164:562-565.
77. Takahashi R., Toh U., Iwakuma N., Takenaka M., Otsuka H., Furukawa M., et al. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res. 2014, 16:R70.
78. Thundimadathil J. Cancer treatment using peptides: current therapies and future prospects. J. Amino Acids 2012, 2012:967347.
79. van Luijn M.M., van den Ancker W., Chamuleau M.E., Zevenbergen A., Westers T.M., Ossenkoppele G.J., et al. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. Cancer Res. 2011, 71:2507-2517.
80. Vassilaros S., Tsibanis A., Tsikkinis A., Pietersz G.A., McKenzie I.F., Apostolopoulos V. Up to 15-year clinical follow-up of a pilot phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy 2013, 5:1177-1182.
81. Vlad A.M., Finn O.J. Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis. 2004, 20:73-79.
82. Vlad A.M., Kettel J.C., Alajez N.M., Carlos C.A., Finn O.J. MUC1 immunobiology: from discovery to clinical applications. Adv. Immunol. 2004, 82:249-293.
83. Wu Y.L., Park K., Soo R.A., Sun Y., Tyroller K., Wages D., et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011, 11:430.
84. Yu Z., Theoret M.R., Touloukian C.E., Surman D.R., Garman S.C., Feigenbaum L., et al. Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J. Clin. Invest. 2004, 114:551-559.
85. Zhang J., Xu Z., Zhou X., Zhang H., Yang N., Wu Y., et al. Loss of expression of MHC class I-related chain A (MICA) is a frequent event and predicts poor survival in patients with hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 2014, 7:3123-3131.